Boston Scientific scores FDA nod for personalized pain device

Marlborough-based Boston Scientific said Thursday that the FDA approved a first-of-its-kind device that uses electrical pulses to treat chronic pain. Boston Scientific (NYSE: BSX) said that the device, called the Spectra WaveWriter, was the first product approved by the FDA that can simultaneously provide two types of pain relief: paresthesia-based therapy, in which patients feel a slight tingling sensation, and sub-perception therapy, in which there is no such sensation. The device is designed…
Source: bizjournals.com Health Care:Pharmaceuticals headlines - Category: Pharmaceuticals Authors: Source Type: news